These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 8935328

  • 1. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E, Kanba S, Koshikawa H, Nibuya M, Yagi G, Asai M.
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [Abstract] [Full Text] [Related]

  • 2. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R, Zumárraga M, Basterreche N, Arrúe A, Anguiano JB.
    Psychiatry Res; 2007 May 30; 151(1-2):163-8. PubMed ID: 17434602
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K, Tsuchida K, Kanzaki A, Ujike H, Hamamura T, Kondo K, Mutoh S, Miyanagi K, Kuroda S, Otsuki S.
    Biol Psychiatry; 1995 Nov 15; 38(10):639-48. PubMed ID: 8555375
    [Abstract] [Full Text] [Related]

  • 5. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI, Sharma RP, Janicak PG, Davis JM.
    Psychopharmacol Bull; 1990 Nov 15; 26(3):361-5. PubMed ID: 2274637
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N, Kondo T, Mihara K, Suzuki A, Yasui-Furukori N.
    Psychiatry Clin Neurosci; 2007 Apr 15; 61(2):174-80. PubMed ID: 17362435
    [Abstract] [Full Text] [Related]

  • 9. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar 15; 30(2):286-91. PubMed ID: 16386826
    [Abstract] [Full Text] [Related]

  • 10. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
    Zhang ZJ, Reynolds GP, Ramchand C, Peet M, Shah S.
    Acta Pharmacol Sin; 2001 Jan 15; 22(1):76-80. PubMed ID: 11730567
    [Abstract] [Full Text] [Related]

  • 11. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I, Takeuchi S, Katsumi A, Mori A, Kanno K, Yang Q, Mashiko H, Numata Y, Niwa S.
    J Clin Psychopharmacol; 2012 Feb 15; 32(1):106-9. PubMed ID: 22198450
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The characteristics of side-effects of bromperidol in schizophrenic patients.
    Yasui-Furukori N, Kondo T, Ishida M, Tanaka O, Mihara K, Kaneko S, Otani K.
    Psychiatry Clin Neurosci; 2002 Feb 15; 56(1):103-6. PubMed ID: 11929578
    [Abstract] [Full Text] [Related]

  • 15. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
    Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG.
    Psychopharmacol Bull; 1992 Feb 15; 28(1):101-7. PubMed ID: 1609034
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC, Bravin S, Fabiano L, Vanni S, Boscati L, Invernizzi G.
    Encephale; 1995 Feb 15; 21(5):555-8. PubMed ID: 8529564
    [Abstract] [Full Text] [Related]

  • 18. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S, Iwamoto N, Arai H.
    Biol Psychiatry; 1997 Apr 15; 41(8):857-64. PubMed ID: 9099412
    [Abstract] [Full Text] [Related]

  • 19. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC.
    Biol Psychiatry; 1996 Feb 01; 39(3):213-5. PubMed ID: 8837983
    [No Abstract] [Full Text] [Related]

  • 20. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E, Cocconcelli C, Canova L, Faravelli C, Marchetti FP, Mariani G, Rapisarda V.
    Minerva Psichiatr; 1996 Mar 01; 37(1):39-44. PubMed ID: 8926856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.